Many studies have reported high expression of SRD5A3 in liver, breast, endometrial, and prostate cancers, and its high expression is associated with poor prognosis [19–21], which is a cancer-promoting effect and is involved in the proliferation of cancer cells [16,22]. This evidence concerns the gene SRD5A3 and prostate carcinoma.